These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24016786)

  • 21. Antiplatelet therapy in acute coronary syndromes.
    Barker CM; Price MJ
    Curr Cardiol Rep; 2008 Jul; 10(4):327-33. PubMed ID: 18611368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Novel agents in antiplatelet therapy].
    Ağırbaşlı M; Güvenç H; Cinçin A
    Turk Kardiyol Dern Ars; 2010 Jul; 38(5):369-78. PubMed ID: 21200111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ticagrelor in ACS: redefining a new standard of care?
    Stone GW
    Lancet; 2010 Jan; 375(9711):263-5. PubMed ID: 20079529
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.
    Chatterjee S; Ghose A; Sharma A; Guha G; Mukherjee D; Frankel R
    J Thromb Thrombolysis; 2013 Oct; 36(3):223-32. PubMed ID: 23212803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI?
    Agrawal K; Bhatt DL
    Nat Rev Cardiol; 2013 Mar; 10(3):121-2. PubMed ID: 23319096
    [No Abstract]   [Full Text] [Related]  

  • 27. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clopidogrel in coronary artery disease: update 2012.
    Huber K
    Adv Cardiol; 2012; 47():31-8. PubMed ID: 22906901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Test before you stop.
    Kumar A; Roberts DH
    Arch Surg; 2009 Aug; 144(8):787; author reply 787. PubMed ID: 19687387
    [No Abstract]   [Full Text] [Related]  

  • 30. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
    Christ G; Siller-Matula JM; Francesconi M; Dechant C; Grohs K; Podczeck-Schweighofer A
    BMJ Open; 2014 Oct; 4(10):e005781. PubMed ID: 25361837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents].
    Enar R
    Turk Kardiyol Dern Ars; 2013 Mar; 41(2):166-71. PubMed ID: 23666308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor.
    Dobesh PP; Varnado S; Doyle M
    Curr Pharm Des; 2016; 22(13):1918-32. PubMed ID: 26642781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
    Lhermusier T; Lipinski MJ; Tantry US; Escarcega RO; Baker N; Bliden KP; Magalhaes MA; Ota H; Tian W; Pendyala L; Minha S; Chen F; Torguson R; Gurbel PA; Waksman R
    Am J Cardiol; 2015 Mar; 115(6):716-23. PubMed ID: 25728845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiplatelet agents make a comeback in ST-elevation myocardial infarction.
    Wiviott SD; de Lemos JA
    Am Heart J; 2007 Oct; 154(4):603-6. PubMed ID: 17892976
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.
    Reese ES; Daniel Mullins C; Beitelshees AL; Onukwugha E
    Pharmacotherapy; 2012 Apr; 32(4):323-32. PubMed ID: 22461122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
    Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New antiplatelet drugs: beyond aspirin and clopidogrel.
    Siddique A; Butt M; Shantsila E; Lip GY
    Int J Clin Pract; 2009 May; 63(5):776-89. PubMed ID: 19392926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor.
    De Servi S; Navarese EP; D'Urbano M; Savonitto S
    Curr Med Res Opin; 2011 Nov; 27(11):2117-22. PubMed ID: 21919581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
    O'Donoghue ML; Braunwald E; Antman EM; Murphy SA; Bates ER; Rozenman Y; Michelson AD; Hautvast RW; Ver Lee PN; Close SL; Shen L; Mega JL; Sabatine MS; Wiviott SD
    Lancet; 2009 Sep; 374(9694):989-997. PubMed ID: 19726078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is prasugrel more effective than clopidogrel at preventing future cardiac events?
    Lange CG
    JAAPA; 2011 Feb; 24(2):52, 55. PubMed ID: 21387971
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.